drugset / Trial / NCT03742414
Seal, Stopping Eczema and Allergy Study
Phase 2
Active not recruiting
398 enrolled
Kari Nadeau, MD, PhD
Children's Hospital Medical Center, Cincinnati · collabGuy's and St Thomas' NHS Foundation Trust · collabHarvard School of Public Health (HSPH) · collabKing's College London · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collabNational Jewish Health · collabStanford University · collabUniversity of Chicago · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
Timeline
- Start
- 2021-06-30
- Primary completion
- 2028-05-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EpiCeram | Unknown | — | — |
| Subject | Fluticasone propionate | Other / unclassified | 0.05 % | Topical |